Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
Occurrence of the BCR-ABL[superscript T315I] gatekeeper mutation is among the most pressing challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors have multiple targets and pleiotropic effects that could be exploited for their synergistic potential. Testing combinati...
Príomhchruthaitheoirí: | , , , , , , , , , , , , , |
---|---|
Rannpháirtithe: | |
Formáid: | Alt |
Teanga: | en_US |
Foilsithe / Cruthaithe: |
Nature Publishing Group
2014
|
Rochtain ar líne: | http://hdl.handle.net/1721.1/89043 https://orcid.org/0000-0002-1545-1651 |